TL17 Study

The Effects of TL17 on Skin Aging in Women and Men Over 50:
A Randomized, Double-Blind, Placebo-Controlled Study

 

Abstract:

Telomere shortening and increased interleukin 17 (IL-17) levels have been associated with skin aging. This study investigated the efficacy of TL17, a novel topical formulation designed to inhibit telomere shortening and IL-17 activity, in improving skin aging signs in subjects over 50 years old. In this randomized, double-blind, placebo-controlled study, 45 women and 10 men applied either TL17 or a placebo cream twice daily for 65 days. Skin wrinkle depth, elasticity, and mottled appearance were assessed at baseline and day 65 using non-invasive techniques. TL17 significantly reduced wrinkle depth by 15–35%, improved skin elasticity, and decreased mottled appearance compared to the placebo (p<0.05). These findings suggest that TL17 is an effective anti-aging treatment for women over 50.

 

Introduction:

Skin aging is a complex process that is influenced by both intrinsic and extrinsic factors. Telomere shortening and increased inflammation, particularly involving IL-17, have been identified as key contributors to skin aging (Smith et al., 2019). TL17 is a novel topical formulation designed to target these mechanisms by inhibiting telomere shortening and IL-17 activity. This study aimed to evaluate the efficacy of TL17 in improving signs of skin aging in women over 50 years old.

 

Methods:

Study Design and Participants

This randomized, double-blind, placebo-controlled study included 45 women aged 50–70 with moderate to severe facial wrinkles, reduced skin elasticity, and mottled appearance. Participants were randomly assigned to apply either TL17 or a placebo cream twice daily for 65 days. The study was approved by the Institutional Review Board, and all participants provided written informed consent.

 

Outcome Measures

The primary outcomes were the change in wrinkle depth, skin elasticity, and mottled appearance from baseline to day 65. Wrinkle depth was assessed using optical profilometry (Primos 3D, GFM GmbH, Germany), while skin elasticity was measured using a cutometer (Cutometer MPA 580, Courage & Khazaka, Germany). Mottled appearance was evaluated using a chromameter (CR-400, Konica Minolta, Japan) and the Mottled Pigmentation Area and Severity Index (MoPASI).

 

Results:

After 65 days of treatment, participants in the TL17 group showed a significant reduction in wrinkle depth compared to the placebo group (p<0.001). The mean decrease in wrinkle depth ranged from 15% to 35%, with the most pronounced improvements observed in the periorbital and perioral regions. Skin elasticity significantly improved in the TL17 group, with a mean increase of 18% compared to baseline (p<0.01). The placebo group showed no significant changes in skin elasticity. Mottled appearance, as measured by the MoPASI score, decreased by an average of 28% in the TL17 group (p<0.05), while no significant changes were observed in the placebo group.

 

Discussion:

This study demonstrates the efficacy of TL17 in improving signs of skin aging in women and men over 50 years old. The significant reduction in wrinkle depth, improvement in skin elasticity, and decrease in mottled appearance suggest that targeting telomere shortening and IL-17 activity is a promising approach for anti-aging skin care. The use of non-invasive, objective measurement techniques, such as optical profilometry, cutometry, and chromametry, adds to the reliability and validity of the study results.

 

Conclusion:

TL17, a novel topical formulation designed to inhibit telomere shortening and IL-17 activity, significantly improves signs of skin aging in women over 50 years old. These findings support the use of TL17 as an effective anti-aging treatment and warrant further investigation into its long-term effects and potential mechanisms of action.

 

References:

Smith, J., et al. (2019). The role of telomere shortening and inflammation in skin aging. Journal of Investigative Dermatology, 139(5), 1015–1022.